Several research firms recently commented on AMPH. Jefferies Group LLC set a $21.00 target price on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, April 20th. Piper Jaffray Companies set a $20.00 target price on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday. BMO Capital Markets reaffirmed a “hold” rating and set a $16.00 target price on shares of Amphastar Pharmaceuticals in a report on Monday. BidaskClub lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Finally, TheStreet raised Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a report on Monday, June 26th.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has earned a consensus recommendation of “Buy” from the nine analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $18.40.
In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 11th. The stock was sold at an average price of $15.43, for a total value of $115,725.00. Following the sale, the director now directly owns 30,500 shares of the company’s stock, valued at $470,615. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jason B. Shandell sold 11,482 shares of the firm’s stock in a transaction that occurred on Wednesday, May 31st. The shares were sold at an average price of $16.92, for a total value of $194,275.44. Following the completion of the sale, the director now directly owns 241,342 shares in the company, valued at $4,083,506.64. The disclosure for this sale can be found here. Over the last three months, insiders sold 43,982 shares of company stock worth $735,850. 11.10% of the stock is owned by corporate insiders.
Hedge funds have recently modified their holdings of the stock. Rothschild Asset Management Inc. acquired a new stake in shares of Amphastar Pharmaceuticals during the first quarter valued at approximately $9,056,000. Citadel Advisors LLC raised its stake in shares of Amphastar Pharmaceuticals by 1,823.3% in the first quarter. Citadel Advisors LLC now owns 355,566 shares of the company’s stock valued at $5,156,000 after buying an additional 337,079 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Amphastar Pharmaceuticals by 68.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 800,900 shares of the company’s stock valued at $14,753,000 after buying an additional 324,043 shares during the last quarter. State Street Corp raised its stake in shares of Amphastar Pharmaceuticals by 11.1% in the first quarter. State Street Corp now owns 1,062,439 shares of the company’s stock valued at $15,406,000 after buying an additional 106,448 shares during the last quarter. Finally, Sei Investments Co. raised its stake in shares of Amphastar Pharmaceuticals by 20,071.0% in the first quarter. Sei Investments Co. now owns 103,074 shares of the company’s stock valued at $1,495,000 after buying an additional 102,563 shares during the last quarter. 44.72% of the stock is currently owned by institutional investors.
Shares of Amphastar Pharmaceuticals (AMPH) traded down 2.22% on Friday, hitting $16.30. The company had a trading volume of 68,360 shares. Amphastar Pharmaceuticals has a 52 week low of $12.05 and a 52 week high of $21.75. The company has a market capitalization of $745.51 million, a price-to-earnings ratio of 85.79 and a beta of 1.65. The stock’s 50-day moving average is $17.52 and its 200 day moving average is $15.94.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Monday, May 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.06 by $0.03. The company had revenue of $56.67 million for the quarter, compared to analyst estimates of $63.74 million. Amphastar Pharmaceuticals had a return on equity of 2.69% and a net margin of 3.54%. The firm’s revenue was down 4.5% on a year-over-year basis. During the same period last year, the business earned $0.12 earnings per share. Equities analysts expect that Amphastar Pharmaceuticals will post $0.40 EPS for the current year.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.